[Author Notes: This article has been modified from its original content. The original article stated that PDL's pre-settlement blended royalty rate was higher than the new worldwide royalty rate of 2.125%. The company claims this is factually incorrect. The company states the pre-settlement blended royalty rate was 1.9% and the new worldwide royalty rate is 2.125%, an increase. This is impossible to verify without access to internal documents, and the blended rate claimed by the company probably includes Lucentis sales, which were all subjected to the tiered U.S. rates and are now gone, so the blended rate considered by the company would not be easily comparable.]
I already covered PDL Biopharma (PDLI) in two past articles (...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: